FDA Approved: SARCLISA — Supplemental Application (Sanofi-Aventis U.S. LLC)

View source ↗

Summary

The FDA approved a supplemental application for Sarclisa (isatuximab) from Sanofi to expand its label for use in multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• SARCLISA (isatuximab)

Snippet

SUPPL AP for SARCLISA (ISATUXIMAB)